HomeCompareLDSF vs MRK

LDSF vs MRK: Dividend Comparison 2026

LDSF yields 4.61% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $3.7K in total portfolio value
10 years
LDSF
LDSF
● Live price
4.61%
Share price
$18.92
Annual div
$0.87
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.0K
Annual income
$619.36
Full LDSF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — LDSF vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLDSFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LDSF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LDSF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LDSF
Annual income on $10K today (after 15% tax)
$391.84/yr
After 10yr DRIP, annual income (after tax)
$526.46/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, MRK beats the other by $281.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LDSF + MRK for your $10,000?

LDSF: 50%MRK: 50%
100% MRK50/50100% LDSF
Portfolio after 10yr
$28.9K
Annual income
$784.83/yr
Blended yield
2.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

LDSF
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LDSF buys
0
MRK buys
0
No recent congressional trades found for LDSF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLDSFMRK
Forward yield4.61%3.25%
Annual dividend / share$0.87$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$27.0K$30.7K
Annual income after 10y$619.36$950.29
Total dividends collected$5.4K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LDSF vs MRK ($10,000, DRIP)

YearLDSF PortfolioLDSF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,161$460.99$11,192$351.54$31.00MRK
2$12,423$480.85$12,524$392.70$101.00MRK
3$13,793$500.22$14,015$438.65$222.00MRK
4$15,277$519.04$15,682$489.96$405.00MRK
5$16,884$537.29$17,547$547.23$663.00MRK
6$18,621$554.95$19,632$611.16$1.0KMRK
7$20,497$572.00$21,963$682.53$1.5KMRK
8$22,520$588.42$24,571$762.18$2.1KMRK
9$24,700$604.21$27,486$851.08$2.8KMRK
10$27,049$619.36$30,745$950.29$3.7KMRK

LDSF vs MRK: Complete Analysis 2026

LDSFStock

The First Trust Low Duration Strategic Focus ETF (the "Fund") seeks to generate current income, with a secondary objective of preservation of capital. Under normal market conditions, the Fund seeks to achieve its investment objectives by investing at least 80% of its net assets (including investment borrowings) in a portfolio of U.S.-listed exchange-traded funds ("ETFs") that principally invest in income-generating securities that provide the Fund with an effective portfolio duration of three years or less.

Full LDSF Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this LDSF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LDSF vs SCHDLDSF vs JEPILDSF vs OLDSF vs KOLDSF vs MAINLDSF vs JNJLDSF vs ABBVLDSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.